PMID- 12816876 OWN - NLM STAT- MEDLINE DCOM- 20040204 LR - 20190508 IS - 1524-4636 (Electronic) IS - 1079-5642 (Linking) VI - 23 IP - 9 DP - 2003 Sep 1 TI - Low-level endotoxin induces potent inflammatory activation of human blood vessels: inhibition by statins. PG - 1576-82 AB - BACKGROUND: Low-level endotoxemia (ie, >or=50 pg/mL) in apparently healthy subjects was recently identified as a powerful, independent risk factor for atherosclerosis. METHODS AND RESULTS: We treated human saphenous veins (HSVs) with low levels of endotoxin. Release of the proinflammatory chemokines interleukin-8 (IL-8) and monocyte chemoattractant protein-1 (MCP-1) was measured by ELISA. Superoxide was determined by using the fluorescent probe dihydroethidium (HE), and monocyte binding was assessed with calcein-labeled U-937 cells. Three- to 4-fold increases in MCP-1 and IL-8 release were observed at endotoxin concentrations of 100 pg/mL; these increases were inhibited by the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor atorvastatin. Studies in cultured endothelial cells suggest that the mechanism is related to inhibition of isoprenylation (ie, geranylgeranylation) rather than cholesterol formation. Endotoxin produced dose-dependent increases in HE fluorescence that were inhibited by the superoxide dismutase mimics Tiron and MnTBAP. Endotoxin potently induced U-937 cell binding to HSV; binding was inhibited by both Tiron and atorvastatin. Toll-like receptor-4 expression was detected in cultured HSV endothelial and smooth muscle cells and in intact HSV. CONCLUSIONS: Clinically relevant levels of endotoxin, as reported in ambulatory populations, have profound inflammatory effects on intact HSV. Inhibition of endotoxin-induced vascular inflammation might contribute to the beneficial effects of statins in treating atherosclerosis. FAU - Rice, James B AU - Rice JB AD - Department of Internal Medicine, University of Iowa College of Medicine, Iowa City, IA 52242, USA. FAU - Stoll, Lynn L AU - Stoll LL FAU - Li, Wei-Gen AU - Li WG FAU - Denning, Gerene M AU - Denning GM FAU - Weydert, Jamie AU - Weydert J FAU - Charipar, Elizabeth AU - Charipar E FAU - Richenbacher, Wayne E AU - Richenbacher WE FAU - Miller, Francis J Jr AU - Miller FJ Jr FAU - Weintraub, Neal L AU - Weintraub NL LA - eng GR - K08 HL003669-04/HL/NHLBI NIH HHS/United States GR - K08 HL003669-05/HL/NHLBI NIH HHS/United States GR - HL62984/HL/NHLBI NIH HHS/United States GR - HL49264/HL/NHLBI NIH HHS/United States PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Research Support, U.S. Gov't, Non-P.H.S. PT - Research Support, U.S. Gov't, P.H.S. DEP - 20030619 PL - United States TA - Arterioscler Thromb Vasc Biol JT - Arteriosclerosis, thrombosis, and vascular biology JID - 9505803 RN - 0 (Chemokine CCL2) RN - 0 (Endotoxins) RN - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors) RN - 0 (Interleukin-8) SB - IM MH - Blood Vessels/drug effects/metabolism/*physiology MH - Cell Line, Tumor MH - Chemokine CCL2/metabolism MH - Coronary Vessels/cytology/drug effects/metabolism/physiology MH - Endothelium, Vascular/cytology/drug effects/metabolism/physiology MH - Endotoxins/*antagonists & inhibitors/*immunology MH - Humans MH - Hydroxymethylglutaryl-CoA Reductase Inhibitors/*pharmacology MH - Inflammation/etiology/metabolism/prevention & control MH - Interleukin-8/metabolism MH - Muscle, Smooth, Vascular/cytology/drug effects/metabolism/physiology MH - Saphenous Vein/drug effects/metabolism/physiology MH - U937 Cells/metabolism EDAT- 2003/06/21 05:00 MHDA- 2004/02/05 05:00 CRDT- 2003/06/21 05:00 PHST- 2003/06/21 05:00 [pubmed] PHST- 2004/02/05 05:00 [medline] PHST- 2003/06/21 05:00 [entrez] AID - 01.ATV.0000081741.38087.F9 [pii] AID - 10.1161/01.ATV.0000081741.38087.F9 [doi] PST - ppublish SO - Arterioscler Thromb Vasc Biol. 2003 Sep 1;23(9):1576-82. doi: 10.1161/01.ATV.0000081741.38087.F9. Epub 2003 Jun 19.